Skip to main content

For urgent surgical problems, please contact the nearest hospital emergency department.

Thyroid Cancer Overview

Typical recovery: Recovery depends on the treatment pathway rather than the diagnosis alone. After uncomplicated thyroid lobectomy or total thyroidectomy, light routine activity is often possible within several days and most wound discomfort improves over one to two weeks. Recovery is longer after extensive central or lateral neck dissection. Radioactive iodine, radiotherapy or systemic therapy have separate recovery and monitoring requirements. Thyroid-cancer surveillance continues long term and is adjusted according to the tumour type, recurrence risk and response to treatment.

Key points

  • Most thyroid nodules are benign; a thyroid nodule is not the same as thyroid cancer.
  • Papillary, follicular and oncocytic carcinomas are grouped as differentiated thyroid cancers and account for most thyroid malignancies.
  • Medullary thyroid carcinoma and anaplastic thyroid carcinoma are biologically different diseases and should not simply be managed according to differentiated-thyroid-cancer algorithms.
  • High-quality neck ultrasound is central to preoperative assessment because both the thyroid tumour and cervical lymph nodes influence the surgical plan.
  • Suspicious cervical lymph nodes can be sampled with ultrasound-guided FNA when the result will alter management.
  • The extent of thyroid surgery should be determined by tumour size, location, extrathyroidal extension, nodal or distant disease, pathology, contralateral thyroid disease, need for adjuvant therapy and patient preference.
  • Under the 2025 ATA differentiated-thyroid-cancer guideline, a cancer confined to one lobe measuring 2 cm or less without gross extrathyroidal extension or clinical nodal disease is generally treated with thyroid lobectomy.
  • For a similarly confined differentiated thyroid cancer larger than 2 cm and up to 4 cm, lobectomy or total thyroidectomy may both be appropriate depending on cancer features, the opposite lobe and patient preference.
  • Differentiated thyroid cancers larger than 4 cm, cancers with gross extrathyroidal extension, clinically involved neck nodes or distant metastases generally require total thyroidectomy with appropriate treatment of involved nodes.
  • Completion thyroidectomy is not automatically required after every cancer diagnosis made following lobectomy; the decision depends on final pathology, recurrence risk and whether removal of the remaining lobe would add meaningful benefit.
  • Clinically involved lymph nodes are treated with therapeutic compartment-oriented neck dissection rather than simple removal of one obvious node.
  • Prophylactic neck dissection is not synonymous with thyroid-cancer surgery and is not required for every clinically node-negative low-risk papillary cancer.
  • Radioactive iodine is not automatically given after every total thyroidectomy. Current management is increasingly selective and based on recurrence risk and expected benefit.
  • Many low-risk differentiated thyroid cancers do not benefit from routine radioactive iodine.
  • After total thyroidectomy for differentiated thyroid cancer, serum thyroglobulin and thyroglobulin antibodies can help monitor residual or recurrent disease when interpreted in the appropriate clinical context.
  • TSH suppression is individualised. More aggressive suppression can have cardiovascular and skeletal adverse effects, so the target should reflect recurrence risk and response to therapy rather than being maximally suppressed in every patient.
  • Selected very small, low-risk papillary cancers can be managed with active surveillance in experienced programmes when tumour location, absence of nodal disease, ultrasound quality and patient reliability make surveillance appropriate.
  • Active surveillance is not neglect; it requires a structured ultrasound follow-up programme and clearly defined triggers for intervention.
  • Medullary thyroid carcinoma is assessed with serum calcitonin and CEA and should prompt evaluation for germline RET mutation because a hereditary syndrome can affect the patient and family members.
  • Radioactive iodine is not useful for medullary thyroid carcinoma because C-cell cancers do not take up iodine in the same way as differentiated thyroid cells.
  • Anaplastic thyroid carcinoma is an oncologic emergency that needs rapid multidisciplinary assessment, airway evaluation when relevant, staging and tumour molecular testing because targeted therapy can be important in selected tumours.
  • BRAF V600E testing is particularly important in anaplastic thyroid carcinoma because BRAF-directed targeted treatment can dramatically alter the management of BRAF-mutated disease.
  • The prognosis of thyroid cancer varies greatly by subtype and stage; the generally excellent outlook of small differentiated cancer should not be extrapolated to medullary, poorly differentiated or anaplastic cancer.
  • Long-term follow-up is risk-adapted: surveillance can be reduced after an excellent response in low-risk differentiated cancer and intensified when biochemical, structural or high-risk features persist.

Overview

Thyroid cancer is not a single disease. Differentiated thyroid cancer—mainly papillary, follicular and oncocytic carcinoma—is the most common group and often has an excellent long-term outlook, but treatment should still be tailored to tumour size, local extension, lymph-node or distant spread, pathology and patient factors. Medullary thyroid carcinoma arises from thyroid C cells and follows a different diagnostic and treatment pathway, while anaplastic thyroid carcinoma is rare, aggressive and requires urgent multidisciplinary assessment. Evaluation usually begins with thyroid and neck ultrasound, fine-needle aspiration of suspicious thyroid nodules or lymph nodes, and appropriate thyroid-function testing. When cancer is confirmed or strongly suspected, preoperative assessment focuses on the primary tumour, both thyroid lobes, central and lateral neck lymph nodes, vocal function when indicated, and evidence of disease beyond the neck when clinically relevant. For differentiated thyroid cancer, surgery has become more individualised. Under the 2025 American Thyroid Association guidelines, cancer confined to one lobe and measuring 2 cm or less, without gross extrathyroidal extension or clinical lymph-node disease, is generally treated with lobectomy. For a similarly confined tumour larger than 2 cm and up to 4 cm, lobectomy or total thyroidectomy may both be reasonable depending on tumour characteristics, the opposite thyroid lobe, the need for postoperative radioactive iodine or thyroglobulin-based surveillance, and patient preference. Tumours larger than 4 cm, gross extension outside the thyroid, clinically involved neck nodes or distant metastases generally require total thyroidectomy with appropriate treatment of involved lymph nodes. Therapeutic compartment-oriented neck dissection is performed for clinically significant nodal metastases rather than simply removing isolated visible nodes. Radioactive iodine is no longer automatic after every total thyroidectomy; it is selected according to recurrence risk, postoperative findings and expected benefit. Follow-up can include clinical examination, neck ultrasound, serum thyroglobulin and thyroglobulin antibodies after appropriate differentiated-cancer treatment, and thyroid hormone therapy with the degree of TSH suppression adjusted to recurrence risk and treatment response. Carefully selected very small low-risk papillary cancers can sometimes be managed with active surveillance rather than immediate surgery in experienced programmes. Medullary thyroid carcinoma requires calcitonin and CEA assessment, evaluation for RET-associated hereditary disease and a different surgical strategy. Anaplastic thyroid cancer requires urgent tissue confirmation, staging, molecular testing and multidisciplinary planning because airway management, targeted therapy, radiotherapy and systemic treatment may be time-critical.

Signs & symptoms

  • A thyroid nodule or neck lump, often discovered incidentally and causing no symptoms.
  • A thyroid nodule that is enlarging or has suspicious ultrasound features.
  • A new or persistent enlarged lymph node in the central or lateral neck.
  • Persistent hoarseness or voice change.
  • Difficulty swallowing or a feeling of neck pressure in larger tumours.
  • Breathing difficulty or stridor in advanced local disease.
  • A rapidly enlarging hard neck mass, particularly concerning for aggressive thyroid malignancy such as anaplastic carcinoma or lymphoma.
  • Many differentiated thyroid cancers cause no symptoms and are detected during imaging or evaluation of a thyroid nodule.

How assessment and treatment are planned

  1. 1

    Review the thyroid ultrasound, cytology or biopsy diagnosis and relevant clinical history.

  2. 2

    Perform a focused examination of the thyroid, cervical lymph-node compartments and voice.

  3. 3

    Check thyroid function and any disease-specific laboratory tests needed for the suspected cancer subtype.

  4. 4

    Perform high-quality ultrasound of the thyroid and central and lateral neck before surgery for differentiated thyroid cancer.

  5. 5

    Sample suspicious lymph nodes with ultrasound-guided FNA when confirmation will influence the surgical plan.

  6. 6

    Assess vocal-cord function when there is preoperative voice change, previous neck surgery, invasive tumour or another clinical indication.

  7. 7

    Use cross-sectional imaging such as contrast-enhanced CT when there is bulky nodal disease, substernal extension, invasive tumour, airway or oesophageal concern, or anatomy that ultrasound cannot adequately define.

  8. 8

    For differentiated thyroid cancer, determine whether lobectomy, total thyroidectomy or active surveillance is appropriate using tumour size, location, extrathyroidal extension, nodal status, contralateral disease, recurrence risk and patient preference.

  9. 9

    Perform therapeutic central or lateral compartment neck dissection when clinically significant nodal metastases are present and surgery is appropriate.

  10. 10

    Review final histopathology to establish tumour subtype, size, margins, vascular invasion, extrathyroidal extension, lymph-node burden and other recurrence-risk features.

  11. 11

    Use postoperative staging and ATA recurrence-risk assessment to decide whether radioactive iodine is likely to provide benefit after total thyroidectomy.

  12. 12

    Plan thyroid-hormone therapy and TSH targets according to risk and treatment response.

  13. 13

    Arrange risk-adapted follow-up using clinical examination, neck ultrasound and appropriate tumour markers.

  14. 14

    For medullary thyroid carcinoma, measure calcitonin and CEA, assess for RET mutation and stage appropriately before definitive treatment whenever feasible.

  15. 15

    For anaplastic thyroid carcinoma, obtain rapid tissue diagnosis, stage promptly, assess airway and molecular profile, and coordinate endocrine surgery, medical oncology and radiation oncology without unnecessary delay.

Preparation

  • Bring thyroid ultrasound reports and, when possible, the actual ultrasound images.
  • Bring FNA cytology, core-biopsy or previous thyroid histopathology reports.
  • Bring previous CT, MRI, PET or nuclear-medicine imaging if already performed.
  • Bring recent thyroid-function tests and any thyroglobulin, calcitonin or CEA results if relevant.
  • Tell the surgeon about previous thyroid or neck surgery and any history of voice change.
  • Mention previous head or neck irradiation.
  • Discuss family history of thyroid cancer, medullary thyroid carcinoma, pheochromocytoma or MEN2-related disease.
  • Bring a current medication list, particularly anticoagulants and antiplatelet medicines.
  • Do not stop blood-thinning medicines without a specific perioperative plan.
  • If surgery is planned, discuss whether the expected procedure is lobectomy, total thyroidectomy, central neck dissection, lateral neck dissection or a combination and why that extent is appropriate.
  • Ask how final pathology could change postoperative decisions such as completion thyroidectomy, radioactive iodine or surveillance.

Recovery and aftercare

  • Attend postoperative review to discuss final histopathology because the definitive risk assessment may differ from the preoperative impression.
  • After total thyroidectomy, take levothyroxine as prescribed because thyroid-hormone replacement is lifelong.
  • After lobectomy, check thyroid function because some patients remain euthyroid while others later require levothyroxine.
  • Follow calcium-monitoring and supplementation instructions after bilateral thyroid surgery when appropriate.
  • Report increasing neck swelling, breathing difficulty or rapidly progressive symptoms urgently after surgery.
  • Report persistent or worsening voice change.
  • If radioactive iodine is recommended, follow the nuclear-medicine preparation and radiation-safety instructions.
  • Attend risk-adapted neck ultrasound and tumour-marker surveillance rather than arranging tests at arbitrary intervals.
  • After differentiated thyroid cancer, take levothyroxine at the TSH target recommended for your recurrence risk and treatment response rather than deliberately suppressing TSH without supervision.
  • After medullary thyroid carcinoma, follow calcitonin and CEA surveillance and any hereditary-cancer recommendations.
  • After anaplastic or advanced thyroid cancer, continue coordinated multidisciplinary follow-up because treatment may involve surgery, radiotherapy, targeted therapy or systemic therapy.

Risks and possible complications

  • Persistent or recurrent cancer in the thyroid bed or neck lymph nodes.
  • Distant metastasis in a minority of patients, depending on cancer subtype and risk features.
  • Need for completion thyroidectomy when final pathology shows features that make additional surgery beneficial.
  • Need for central or lateral neck dissection when metastatic lymph nodes are present.
  • After thyroid surgery: bleeding or neck haematoma.
  • After thyroid surgery: temporary or permanent recurrent laryngeal nerve injury causing voice change.
  • After bilateral thyroid surgery: temporary or permanent hypocalcaemia from parathyroid dysfunction.
  • Need for lifelong levothyroxine after total thyroidectomy.
  • Potential salivary-gland, tear-duct and other radiation-related adverse effects when radioactive iodine is used.
  • Atrial fibrillation and bone loss can occur when TSH is suppressed more aggressively than clinically necessary for prolonged periods.
  • Medullary thyroid carcinoma can be hereditary, creating implications for relatives if a germline RET mutation is found.
  • Anaplastic thyroid carcinoma can progress rapidly and threaten the airway or other vital structures.

When to seek medical care

  • SOON: A newly diagnosed or cytologically suspicious thyroid cancer that has not yet been staged or surgically assessed.
  • SOON: A persistent or enlarging hard thyroid nodule.
  • SOON: A new or enlarging cervical lymph node associated with a thyroid nodule or previous thyroid cancer.
  • SOON: Persistent hoarseness or voice change.
  • SOON: Progressive swallowing difficulty or neck pressure.
  • SOON: A new neck lump after previous thyroid-cancer treatment.
  • SOON: Rising thyroid-cancer tumour markers or a new abnormality on surveillance imaging.
  • URGENT: Rapid enlargement of a thyroid or neck mass over days to weeks.
  • URGENT: Stridor, rapidly progressive breathing difficulty or signs of airway compromise.
  • URGENT: Rapidly worsening swallowing difficulty associated with an enlarging hard neck mass.
  • URGENT: Suspected anaplastic thyroid carcinoma because diagnostic, airway and oncologic decisions may be time-sensitive.

Myth vs fact

Frequently asked questions

Sources

Medically reviewed by Dr. Shams Alam Mohammed Tahir, MBBS, MS (General Surgery). Last reviewed 2026-09-20.

WhatsApp